First Horizon Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.78M | Buy |
19,719
+404
| +2% | +$186K | 0.23% | 120 |
|
|
2025
Q1 | $9.36M | Buy |
19,315
+17,116
| +778% | +$7.98M | 0.26% | 118 |
|
|
2024
Q4 | $886K | Buy |
2,199
+36
| +2% | +$16.7K | 0.02% | 263 |
|
|
2024
Q3 | $1.01M | Sell |
2,163
-27
| -1% | -$13K | 0.03% | 254 |
|
|
2024
Q2 | $1.03M | Sell |
2,190
-24
| -1% | -$10.4K | 0.03% | 251 |
|
|
2024
Q1 | $925K | Buy |
2,214
+1,277
| +136% | +$540K | 0.03% | 260 |
|
|
2023
Q4 | $381K | Buy |
937
+78
| +9% | +$28.8K | 0.01% | 361 |
|
|
2023
Q3 | $299K | Buy |
859
+543
| +172% | +$190K | 0.01% | 394 |
|
|
2023
Q2 | $111K | Sell |
316
-17
| -5% | -$5.73K | ﹤0.01% | 614 |
|
|
2023
Q1 | $105K | Buy |
333
+4
| +1% | +$1.2K | ﹤0.01% | 627 |
|
|
2022
Q4 | $95K | Buy |
329
+24
| +8% | +$7.31K | ﹤0.01% | 634 |
|
|
2022
Q3 | $88K | Buy |
305
+15
| +5% | +$4.32K | ﹤0.01% | 648 |
|
|
2022
Q2 | $81K | Buy |
290
+170
| +142% | +$45.5K | ﹤0.01% | 755 |
|
|
2022
Q1 | $31K | Sell |
120
-39
| -25% | -$9.26K | ﹤0.01% | 779 |
|
|
2021
Q4 | $34K | Sell |
159
-88
| -36% | -$17.1K | ﹤0.01% | 1091 |
|
|
2021
Q3 | $44K | Buy |
247
+3
| +1% | +$586 | ﹤0.01% | 962 |
|
|
2021
Q2 | $49K | Sell |
244
-189
| -44% | -$39.5K | ﹤0.01% | 794 |
|
|
2021
Q1 | $92K | Buy |
433
+189
| +77% | +$41.5K | 0.01% | 531 |
|
|
2020
Q4 | $57K | Hold |
244
| – | – | ﹤0.01% | 560 |
|
|
2020
Q3 | $66K | Sell |
244
-25
| -9% | -$6.9K | ﹤0.01% | 472 |
|
|
2020
Q2 | $77K | Hold |
269
| – | – | 0.01% | 435 |
|
|
2020
Q1 | $63K | Buy |
269
+34
| +14% | +$7.8K | 0.01% | 441 |
|
|
2019
Q4 | $51K | Buy |
235
+95
| +68% | +$19.2K | ﹤0.01% | 571 |
|
|
2019
Q3 | $23K | Sell |
140
-52
| -27% | -$9.2K | ﹤0.01% | 802 |
|
|
2019
Q2 | $35K | Buy |
192
+3
| +2% | +$524 | ﹤0.01% | 680 |
|
|
2019
Q1 | $35K | Buy |
189
+178
| +1,618% | +$32.9K | ﹤0.01% | 621 |
|
|
2018
Q4 | $1K | Sell |
11
-2
| -15% | -$347 | ﹤0.01% | 1461 |
|
|
2018
Q3 | $2K | Sell |
13
-119
| -90% | -$21.2K | ﹤0.01% | 1435 |
|
|
2018
Q2 | $22K | Hold |
132
| – | – | ﹤0.01% | 871 |
|
|
2018
Q1 | $21K | Hold |
132
| – | – | ﹤0.01% | 794 |
|
|
2017
Q4 | $20K | Sell |
132
-132
| -50% | -$19.5K | ﹤0.01% | 822 |
|
|
2017
Q3 | $39K | Sell |
264
-10
| -4% | -$1.5K | ﹤0.01% | 560 |
|
|
2017
Q2 | $41K | Sell |
274
-75
| -21% | -$9.03K | ﹤0.01% | 541 |
|
|
2017
Q1 | $41K | Buy |
349
+56
| +19% | +$4.93K | ﹤0.01% | 581 |
|
|
2016
Q4 | $23K | Hold |
293
| – | – | ﹤0.01% | 757 |
|
|
2016
Q3 | $23K | Sell |
293
-81
| -22% | -$7.66K | ﹤0.01% | 751 |
|
|
2016
Q2 | $31K | Sell |
374
-1
| -0.3% | -$86 | ﹤0.01% | 649 |
|
|
2016
Q1 | $32K | Buy |
375
+31
| +9% | +$2.8K | ﹤0.01% | 666 |
|
|
2015
Q4 | $43K | Buy |
344
+36
| +12% | +$4.35K | 0.01% | 520 |
|
|
2015
Q3 | $32K | Buy |
308
+4
| +1% | +$514 | ﹤0.01% | 646 |
|
|
2015
Q2 | $37K | Buy |
304
+76
| +33% | +$9.58K | 0.01% | 630 |
|
|
2015
Q1 | $27K | Buy |
228
+67
| +42% | +$8.03K | ﹤0.01% | 750 |
|
|
2014
Q4 | $19K | Buy |
161
+22
| +16% | +$2.48K | ﹤0.01% | 842 |
|
|
2014
Q3 | $15K | Buy |
139
+8
| +6% | +$762 | ﹤0.01% | 931 |
|
|
2014
Q2 | $11K | Buy |
131
+93
| +245% | +$6.52K | ﹤0.01% | 1019 |
|
|
2014
Q1 | $2K | Sell |
38
-4
| -10% | -$317 | ﹤0.01% | 1243 |
|
|
2013
Q4 | $3K | Sell |
42
-6
| -13% | -$418 | ﹤0.01% | 1191 |
|
|
2013
Q3 | $4K | Buy |
+48
| New | +$3.82K | ﹤0.01% | 996 |
|
Other funds holding VRTX
First Horizon Advisors's VRTX Position: Q2 2025 in Review
First Horizon Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q2 2025, buying an estimated $186K and bringing the position to 19,719 shares worth $8.78M. The position accounts for 0.23% of the portfolio, ranked #120.
First Horizon Advisors first reported a position in VRTX in Q3 2013 and has held it in 48 quarters since. The position peaked at $9.36M in Q1 2025. 1,560 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.
- First Horizon Advisors held 19,719 shares of Vertex Pharmaceuticals worth $8.78M as of Q2 2025.
- First Horizon Advisors bought 404 Vertex Pharmaceuticals shares in Q2 2025, an estimated $186K.
- Vertex Pharmaceuticals made up 0.23% of First Horizon Advisors's portfolio in Q2 2025, its #120 holding.
- First Horizon Advisors first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 48 quarters since.
- First Horizon Advisors's Vertex Pharmaceuticals position peaked at $9.36M in Q1 2025.
- 1,560 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.
Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.